Epithelial and endothelial mesenchymal transition and their role in diabetic kidney disease by Dadras, F. et al.
Journal of Renal Injury Prevention
J Renal Inj Prev. 2018; 7(1): 1-6.
Epithelial and endothelial mesenchymal transition and 
their role in diabetic kidney disease                             
Farahnaz Dadras1, Vida Sheikh2, Farhad Khoshjou2*
1Department of Internal Medicine, Section of Nephrology, Iran University of Medical Sciences, Tehran, Iran  
2Clinical Research Development unit of Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, Iran 
*Corresponding author: Farhad Khoshjou, Email: fakhoshjou@yahoo.com
http://journalrip.com                DOI: 10.15171/jrip.2018.01
Implication for health policy/practice/research/medical education:
Diabetes and its complications including diabetic nephropathy are spreading worldwide. On the other hand, pathophysiology 
of diabetic kidney disease and its modifiers have been studied broadly. This mini-review presents a couple of them, allocated to 
EMT and Endomt, briefly and to the point.
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Diabetic nephropathy (DN) is the main cause of end-stage renal disease. On the other hand, 
there are a couple of evidences, including human studies, which prove the role of epithelial 
mesenchymal transition (EMT) in pathophysiology of DN. EMT is characterized by loss of 
epithelial proteins and gain of mesenchymal markers. EMT is induced via three main conduit; 
TGFβ/Smad, integrin /ILK as well as Wnt/β-catenin pathways. Besides, numerous studies 
illustrated how drugs and agents can modify this phenomenon. On the other hand, endothelial 
mesenchymal transition (EndoMT) has a well-known role in pathophysiology of diabetic 
nephropathy which has been studied in animal and human. Here, several drugs and modifiers 
which have been studied to ffigure out if they can amend nature of EMT or EndoMT are 
reported briefly.
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Diabetic kidney disease (DKD) is a major complication 
of diabetes and is the single largest cause of end-
stage kidney failure (1). During the clinically silent 
stage, structural lesions include glomerular basement 
membrane thickening build up and extreme deposition 
of extracellular matrix (ECM) in the glomerulus and 
interstitial area. It, finally, leads to glomerulosclerosis and 
tubulointerstitial fibrosis as well (2,3). Pathophysiology of 
diabetic nephropathy (DN) has intensively been studied. 
Two of them i.e. epithelial-mesenchymal transition (EMT) 
and endothelial-mesenchymal transition (EndoMT) are 
discussed here. Furthermore, a couple of drugs and agents 
which modify these phenomena are listed. 
Materials and Methods
For this mini-review, we used a variety of sources 
including PubMed, Embase, Scopus and directory of open 
access journals (DOAJ). The search was performed by 
using combinations of the following keywords and or their 
equivalents; epithelial mesenchymal transition, diabetic 
nephropathy, TGFβ/Smad, integrin /ILK, Wnt/β-catenin, 
diabetic kidney disease and endothelial mesenchymal 
transition. Manuscripts published in English as full-text 
articles and or as abstracts were included in the study.
Epithelial-mesenchymal transition 
Epithelial cells are connected exteriorly to basement 
membrane and interiorly cover the lumen of tubules. 
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Sideways, they interrelate with adjacent epithelial cells (4). 
Epithelial-mesenchymal transition (EMT) comprises loss 
of intercellular connections, their detachment from a 
basement membrane, loss of epithelial phenotype markers 
and attain mesenchymal markers and cell progression 
(5). The transition is characterized by loss of epithelial 
proteins such as cytokeratin, and E-cadherin and take 
mesenchymal markers including α-smooth muscle actin 
(α-SMA) and vimentin (6). However, the possession of 
EMT markers in vivo, is often variable, perhaps reflecting 
limited EMT (also termed pre-EMT) (7). 
EMT might be an adaptive reaction of epithelial cells 
to an aggressive milieu. The chemokine slope made 
about tubular sections draw inflammatory cells to the 
tubulointerstitial space. They, in turn, generate matrix 
metalloproteinases (MMPs) and pro-fibrotic cytokines, 
accordingly (8).
MMPs, especially MMP-2 and MMP-9, secreted by 
macrophages and up-regulated by TGF-β1 in kidney 
tubular epithelial cells, have been shown to be pro-fibrotic 
by induction of tubular cells EMT (9). 
MMP-9 decays normal basement membrane collagen 
and postpones degradation and endorses gathering of 
extracellular matrix (10). There is disordered ratio of 
MMP-9 and tissue inhibitor of metalloproteinase in EMT 
(11), including the EMT which takes place in DKD (12).
Glomerular podocytes and endothelial cells also experience 
transition after damage. Phenotypic modification of 
podocytes leads to proteinuria and glomerulosclerosis 
(13). EMT is induced via three main conduits, three 
main converging signaling pathways, which they are 
TGFβ/Smad, integrin/ILK, and Wnt/β-catenin pathways 
(Figure 1). 
TGFβ signaling 
Tian et al explained that the cytoskeleton of proximal 
tubular epithelial cells undertakes notable restructuring 
in reaction to TGF-β (14). They lose their cobblestone 
morphology and become spindle shaped. 
This is accompanied by downregulation of expression of 
E-cadherin, a key constituent of adherents junctions, de 
novo expression of α-SMA and reformation of the actin 
microfibrillar which is characteristic of myofibroblasts. 
Smad proteins principally mediate the signals of TGF-β. 
Non-Smad pathways of TGF-β signaling complicated 
in EMT comprise RhoA, p38 mitogen-activated protein 
kinase (MAPK), and phosphatidyl-3-kinase(PI3K)/AKT. 
Rho kinase, on the other hand, can be motivated by 
sphingosine-1-phosphate (S1P) through its receptor, S1P2. 
Thus, S1P-S1P2 signaling takes part in EMT through Rho 
kinase activation in renal tubules (15).
Integrin/ILK signaling
Integrin linked kinase (ILK) obtains its biologic actions 
by two major characteristics; as a protein kinase and as a 
scaffolding protein (16). As a protein kinase, the catalytic 
activity of ILK renders it to directly phosphorylate a 
number of downstream kinases including GSK-3-β causes 
stabilization of β-catenin (17). This sequentially organizes 
the presentation of a cluster of genes that are fundamental 
for the EMT phenomenon. 
Wnt/βcatenin signaling 
In the lead of fastening to their receptors, Wnt proteins 
provoke a successive signaling, involving GSK-3-β. It, in 
turn, consequences in β-catenin escaping from ubiquitin-
mediated degradation. As a result β-catenin accumulates 
in the cytoplasm and translocates into the nuclei, where it 
stimulates the transcription of Wnt target genes (18).
Endothelial mesenchymal transition (EndoMT)
For the first time, Karasek suggested that endothelial cells 
(EC) are a source of myofibroblasts in fibrotic diseases 
(19). During EndoMT, endothelial cells (EC) lose their 
molecular markers such as VE-cadherin, detach from 
endothelial layer and begin the expression of mesenchymal 
cell products (e.g. α-SMA) (20). 
Molecular mechanisms of EndoMT
TGF‐β‐binding activates Smad‐dependent and Smad‐
independent signaling. Consequently, inception of NOX4 
emergence results in Snail1 provocation of EndoMT. 
Endothelin-1 wields strong collaboration with TGF- β 
effects on EndoMT, as well. Snail1 levels are modulated by 
GSK3‐mediated phosphorylation. 
 Caveolins, on the other hand, are a family of essential 
membrane proteins that are involved in receptor-
independent endocytosis. Caveolin-1 is most prominently 
expressed in endothelial, fibrous, and adipose tissue (21). 
It causes TGF- β receptors internalization and successive 
deprivation (22) (Figure 2).
Evidence of EMT in diabetic nephropathy 
Stimulation of the Wnt/𝛽-catenin signaling pathway 
has been verified to play a role in the pathogenesis and 
progression of DN, and multiple cells are considered to 
be involved in this process, including mesangial cells, 
Figure 1. Three main signaling pathways which lead to 
expression of EMT genes
       Journal of Renal Injury Prevention, Volume 7, Issue 1, March 2018http://journalrip.com                3
EMT and EndoMT in diabetic nephropathy
endothelial cells, podocytes and tubular cells (23). 
Zhou et al showed that levels of 𝛽-catenin and WNT 
proteins are upregulated in the kidney tissues of diabetic 
animal models. Furthermore, activated WNT signaling 
in cultured human renal proximal tubular epithelial cells 
and proteinuria induced by hyperglycemic milieu, could 
be ameliorated by using the antibody (24). 
MicroRNAs 
Micro (mi)RNAs are small noncoding endogenous 
RNA strands that regulate gene expression. For instance 
expression of miRNA192 downregulated by TGFβ 
correlates with fibrosis in human DN (25). On the other 
hand, expression of miRNA377 was upregulated in 
murine models of DN, which led to amplified fibronectin 
production (26). 
Other mediators 
Dai et al showed that high-glucose induces EMT and 
connective tissue growth factor (CTGF) overexpression 
in podocytes which can be attenuated by anti-CTGF 
antibody (27). On the other hand, cytochrome P450 
(CYP) epoxygenases metabolize arachidonic acid into 
epoxyeicosatrienoic acids (EETs). TGF-β1inhibition 
induced by CYP2J2 expression distinguishes key function 
of this axis in pathophysiology DN (28). 
Furthermore, high glucose-induced phenotypic transition 
in podocytes is provoked by PTEN/PI3K/Akt pathway 
(29). High-mobility group AT-hook 2 (HMGA2) plays an 
important role in EMT during DKD, as well (30). 
Role of EndoMT in diabetic kidney disease
Endothelial dysfunction has been postulated to take part 
in the pathogenesis of DN. Both afferent and efferent 
arterioles and glomerular endothelial cells (GEnC) all are 
damaged (31). Zeisberg et al presented the first evidence 
of possible EndoMT in diabetic kidney fibrosis (32). 
They showed that roughly half of fibroblasts expressed 
both endothelial marker and markers of fibroblasts and 
myofibroblasts simultaneously.
Advanced oxidation protein products (AOPP) are 
uremic toxins formed during oxidative stress through 
the reaction of plasma proteins with chlorinated oxidants 
such as hypochlorous acid or chloramines. A study by 
Liang et al showed; AOPP treatment drops expression 
of vascular endothelial CD31 and cadherin and induces 
overexpression of α-smooth muscle actin and vimentin, 
additionally. They conclusively showed that AOPPs 
prompts EndoMT (33). 
Rho-associated kinase 1 (ROCK1) is a protein serine/
threonine kinase. It controls the actomyosin cytoskeleton 
and contributes to processes such as cell motility and 
EMT (34). Peng et al displayed that ROCK1 is induced 
by high glucose and it consequently stimulates EndoMT 
and causing amplified endothelial permeability. Therefore 
inhibition of ROCK1 might be a therapeutic approach for 
avoiding glomerular endothelial dysfunction in emerging 
DN (35). 
Inhibitors of dipeptidyl peptidase 4 or gliptins are a 
category of oral hypoglycemic agents which can be used 
to treat diabetes mellitus type 2. The DPP-4 inhibitor 
linagliptin, as 
Shi et al showed, amends endothelial levels of integrin 
β1. Furthermore, knock downing of DPP-4 results in the 
suppression of TGF-β receptor heterodimer formation, 
and EndoMT, as well (36).
Acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is a 
substrate of angiotensin-converting enzyme (ACE) and an 
endogenous anti-fibrotic molecule that has the potential 
of inhibition of the EndoMT through the restoration of 
FGF receptor (37). 
Serum response factor is a member of transcription factors. 
This protein regulates the activity of many genes and takes 
part in cell differentiation. Increased serum response 
factor (SRF) activity provokes both EMT in podocytes 
(38) and EndoMT of GEnCs in DKD. Targeting SRF by 
small molecule inhibitors (e.g. CCG-1423) is suggested as 
an attractive therapeutic approach for DKD (39). 
SMADs are transducer proteins that transmit extracellular 
signals from TGF-β ligands to the nucleus where they 
stimulate downstream gene transcription. 
Obstruction of EndoMT by Smad3 inhibitor offers a 
new approach to delay the advancement of diabetic 
complications including DKD (40).
Human studies
EMT has also been recognized in biopsies of patients with 
DN (41) and also vimentin immunoreactivity was severely 
illustrated in atrophic diabetic tubules (42).
Li et al showed that ZO-1 and nephrin disappear in the 
glomeruli of human diabetic kidneys. On the other hand, 
FspI, is induced in glomerular podocytes (43). 
Peng et al demonstrated that EndoMT occurs in the 
glomerular endothelium of patients with DKD, showing by 
a decrease in CD31 but an increase in α-SMA expression 
(35). 
Protein C is an anticoagulant serine protease activated 
Figure 2. Molecular factors which induce EndoMT.
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by the blood coagulation pathway (44). Endothelial 
protein C receptor (EPCR) is a receptor for protein C that 
enhances its activation. EPCR delays DN progress. On the 
other hand, EPCR shedding through metalloproteinase 
ADAM17 contributes to the worsening of DKD (45). 
Modifiers and drugs 
A couple of agents and drugs have been studied to show 
their impact on EMT induced by hyperglycemia (Table 1). 
Conclusion
Numerous studies, including experimental animal models 
and tissues from patients, undoubtedly, make obvious 
that EMT and EndoMT cooperate a significant role in the 
pathogenesis of DKD. Several studies evidently point out 
the explanation of molecular mechanisms implicated in 
EMT and EndoMT, making novel molecular targets and 
therapeutic approaches, available to DKD. 
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